Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.42 |
| ▸ | FGF1 | P05230 | 2/20 | 0.39 |
| ▸ | AMY2A | P04746 | 1/20 | 0.37 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | SI | P14410 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10360872 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL22460849 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL12013749 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL7151354 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL7154448 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL313178 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL15925201 | 1.00 | LGALS8 (0.42) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL19425947 | 0.87 | LGALS8 (0.38) | LGALS8FGF1AMY2ASERPINC1LGALS3 | |
| SCHEMBL17986845 | 0.85 | L3MBTL1 (0.37) | LGALS8FGF1AMY2ASERPINC1MGAM | |
| SCHEMBL3903836 | 0.84 | LGALS8 (0.37) | LGALS8AMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| EP-3313849-B1 | NEW HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2023-02-22 | — | — | EP | disclosed |
| CN-107922432-B | Novel hydroxy acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-05-04 | — | — | CN | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10322131-B2 | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-06-18 | — | — | US | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20180185369-A1 | HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2018-07-05 | — | — | US | disclosed |
| EP-3313849-A1 | NEW HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207216-A1 | NEW HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322131-B2 | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | HRH4, HCAR3, HRH3 | LGALS8 4294/4885FGF1 1626/4885AMY2A 1152/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LGALS8 461/4885FGF1 3604/4885AMY2A 1663/4885 |
| US-20180185369-A1 | HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HRH4, HCAR3, HRH3 | LGALS8 4294/4885FGF1 1626/4885AMY2A 1152/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LGALS8 461/4885FGF1 3604/4885AMY2A 1663/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LGALS8 461/4885FGF1 3604/4885AMY2A 1663/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LGALS8 461/4885FGF1 3604/4885AMY2A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.